X hits on this document

390 views

0 shares

0 downloads

0 comments

34 / 136

32

j)

Expense ratios Please refer to the Notes to the Financial Statements in the Annual Financial Statements.

k) Turnover ratios Please refer to the Notes to the Financial Statements in the Annual Financial Statements.

l)

Any material information that will adversely impact the valuation of the scheme Nil

m) Soft dollars received from brokers The Manager does not receive soft commissions or cash rebates from dealing on the Aberdeen Global Opportunities Fund.

n) Key Information on the underlying scheme: Aberdeen Global ‑ World Equity Fund

Top 10 Holdings

  • as at 30 September 2014

Security Names

Roche Holdings Tenaris Novartis Johnson & Johnson CVS Caremark Philip Morris International Royal Dutch Shell B Taiwan Semiconductor Manufacturing Company Shin‑Etsu Chemical British American Tobacco

  • as at 30 September 2013

Security Names

Roche Holdings Vodafone British American Tobacco Philip Morris International Novartis Tenaris Royal Dutch Shell B Standard Chartered Taiwan Semiconductor Manufacturing Company CVS Caremark

Expense ratios

(3)

01 October 2013 to 31 March 2014: 01 October 2012 to 31 March 2013:

Turnover ratios

(4)

01 October 2013 to 30 September 2014: 01 October 2013 to 30 September 2013:

Market Value (S$)

% of Fund

217,897,613

4.2

195,939,109

3.8

187,913,143

3.6

180,292,526

3.5

163,916,341

3.2

160,084,506

3.1

158,203,614

3.0

153,962,731

3.0

152,487,593

2.9

149,339,894

2.9

    • 0.14

      %

    • 0.13

      %

0.00% 0.00%

Market Value (S$)

% of Fund

156,630,401

4.1

119,985,708

3.1

116,962,502

3.1

116,617,988

3.1

116,459,415

3.1

115,982,392

3.0

114,164,555

3.0

113,541,001

3.0

110,017,847

2.9

108,817,982

2.9

Document info
Document views390
Page views390
Page last viewedSat Dec 10 01:52:30 UTC 2016
Pages136
Paragraphs8751
Words36567

Comments